Nr5a2 heterozygosity sensitises to, and cooperates with, inflammation in KRasG12V-driven pancreatic tumourigenesis
Conclusions
A full Nr5a2 dose is required to restore pancreatic homeostasis upon damage and to suppress the KRasG12V-driven mouse pancreatic intraepithelial neoplasia progression, indicating that Nr5a2 is a novel pancreatic tumour suppressor. Nr5a2 could contribute to PDAC through a role in the recovery from pancreatitis-induced damage.
Source: Gut - Category: Gastroenterology Authors: Flandez, M., Cendrowski, J., Canamero, M., Salas, A., del Pozo, N., Schoonjans, K., Real, F. X. Tags: Pancreas and biliary tract, Pancreatitis, Pancreatic cancer Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Epithelial Cancer | Gastroenterology | Genetics | Pancreas | Pancreatic Cancer | Pancreatitis | Statistics